ABSTRACT We report here two genome sequences of a newly designated rhinovirus genotype, RV-C56, which were obtained from respiratory specimens of three patients with acute respiratory illness in 2016 and 2017. To our knowledge, these sequences represent the first near-complete genomes for RV-C56 strains.
R
hinovirus C (RV-C) is one of three rhinovirus species of the Enterovirus (EV) genus in the Picornaviridae family of nonenveloped, single-stranded, positive-sense RNA viruses. RV-C was first described in 2006 from patients with influenza-like illness (1, 2) . RV-C has been associated with more severe respiratory illness than have RV-A and RV-B (3) and is also distinct from RV-A and RV-B in that RV-C is not culturable by conventional cell culture methods (4, 5) .
The California Department of Public Health Viral and Rickettsial Disease Laboratory performs diagnostic testing for many respiratory viruses, including RVs and EVs, using real-time reverse transcription-PCR (RT-PCR) assays adapted from the U.S. Centers for Disease Control and Prevention protocols (6) . Recently, we detected an increasing number of specimens that tested positive for both EV and RV by these assays. Subsequent viral protein 1 (VP1) and genomic investigations identified RV-C from some specimens, including a recent study of RV-C47 (7).
We generated complete protein-coding sequences (CDSs) of three RV-C strains. Nasopharyngeal swab specimens were clarified by centrifugation, 0.4-m filtration, and nuclease treatment prior to extraction using the NucliSENS easyMAG system (bioMérieux, Durham, NC, USA). Extracted RNA was treated with DNase, followed by random RT and subsequent PCR (7, 8) . Libraries were prepared using a Nextera XT kit (Illumina, San Diego, CA, USA) and sequenced (300-cycle paired-end run) on the MiSeq platform (Illumina). The next-generation sequencing (NGS) data were analyzed by an in-house NGS pipeline performing read quality control, de novo assembly, and BLAST analysis (9) . Final consensus genomes were inspected and annotated using Geneious version 11. Average read coverage ranged from 352-to 1,863-fold for the three RV-C genomes.
The genome sequences were confirmed by the Picornaviridae Study Group of the International Committee for the Taxonomy of Viruses (10) as RV-C56. In one instance, twin 1-year-old siblings with a noticeable cough but no fever yielded nearly identical RV-C56 genomes, except for two synonymous nucleotide changes in VP3. We submitted one of the two sequences to GenBank as RV-C56 strain USA/2016/CA-RGDS-1002. We identified a second RV-C56 strain, USA/2017/CA-RGDS-1003, in a 31-year-old female with low-grade fever, shortness of breath, and productive cough who had returned from overseas travel approximately 1 day prior to the onset of the illness. The genome of RV-C56 strain USA/2017/CA-RGDS-1003 shared 99.3% nucleotide identity (NI) to strain USA/2016/CA-RGDS-1002.
No complete CDS of RV-C56 existed prior to this report. Both California RV-C56 strains share 96% NI to a partial capsid sequence reported from Japan in 2014 (GenBank accession number LC004772) (11) . Both California RV-C56 strains shared Ͻ85% NI and Ͻ91% amino acid identity (AI) with VP1 genes from other RV-C genotypes. Compared to the closest full genomes of other RV-C types, the RV-C56 strain USA/2016/CA-RGDS-1002 sequence is missing 26 nucleotides (nt) in the 5= end and 11 nt in the 3= end. The rhinovirus polyprotein can be divided into one structural (P1-capsid) and two nonstructural (P2 and P3) regions. The polyprotein regions of the two RV-C56 genomes reported here all share Ͻ85% NI (P1, P2, and P3) and Ͻ92% AI (P1), Ͻ93% AI (P2), and Ͻ92% AI (P3) with other RV-C genotypes.
Data availability. The genome sequences of RV-C56 strains USA/2016/CA-RGDS-1002 and USA/2017/CA-RGDS-1003 have been deposited in GenBank under the accession numbers MG950178 and MG950179, respectively.
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